Akebia Therapeutics(FRA) AX9

Market Cap€214.81M

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

€0.74

-4.52%

-0.04Today

Akebia Therapeutics Financials at a Glance

Market Cap

€214.81M

Revenue (TTM)

€187.81

Net Income (TTM)

-€25.46

EPS (TTM)

-€0.10

P/E Ratio

-8.13

Dividend

€0.00

Beta (Volatility)

0.07 (Low)

Dividend

€0.00

Beta (Volatility)

0.07 (Low)

Price

€0.74

Volume

Open

€0.74

Price

€0.74

Volume

Open

€0.74

Previous Close

€0.74

Daily Range

€0.74 - €0.74

52-Week Range

€0.71 - €2.76

Estimated Earnings Date

N/A

Dividend

€0.00

Beta (Volatility)

0.07 (Low)

Price

€0.74

Volume

Open

€0.74

Previous Close

€0.74

Daily Range

€0.74 - €0.74

52-Week Range

€0.71 - €2.76

Estimated Earnings Date

N/A

AX9 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Industry

Biotechnology

Sector

Health Care

Employees

194

CEO

John P. Butler, MBA

Website

www.akebia.com

AX9 Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-108.84%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-12.30%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€214.81M

Shares Outstanding

277.11M

Volume

Avg. Volume

512.121

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Akebia Therapeutics Performance Analysis

Akebia Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	EUR 278,297,952	55.4%
2023	2023-12-31	EUR 180,020,526	-35.3%
2024	2024-12-31	EUR 148,082,989	-17.7%
2025	2025-12-31	EUR 209,286,385	41.3%

Akebia Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	EUR -0.49	-65.9%
2023	2023-12-31	EUR -0.26	-47.8%
2024	2024-12-31	EUR -0.30	18.7%
2025	2025-12-31	EUR -0.02	-94.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

€42.25

+0.8%

Gross Profit

€32.78

+0.7%

Gross Margin

77.59%

+0.9%

Market Cap

€214.81M

N/A

Market Cap/Employee

€1.33

N/A

Employees

194

N/A

Net Income

-€7.66

-35.2%

EBITDA

-€3.26

-0.3%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

€321.93

+8.6%

Total Debt

€184.39

+1.0%

Accounts Receivable

€46.80

+0.8%

Inventory

€11.39

+0.8%

Long Term Debt

€141.04

+0.9%

Short Term Debt

€43.35

+1.6%

Return on Assets

-8.48%

+0.6%

Return on Invested Capital

-82.22%

N/A

Free Cash Flow

€1.99

+0.1%

Operating Cash Flow

€2.92

+0.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About AX9

What is the current price of Akebia Therapeutics?

Akebia Therapeutics is trading at €0.74 per share.

What is the 52-week range for Akebia Therapeutics?

Over the past 52 weeks, Akebia Therapeutics has traded between €0.71 and €2.76.

How much debt does Akebia Therapeutics have?

As of the most recent reporting period, Akebia Therapeutics reported total debt of €184.39M.

How much cash does Akebia Therapeutics have on hand?

Akebia Therapeutics reported €137.55M in cash and cash equivalents in its most recent financial results.

What is Akebia Therapeutics’s dividend yield?

Akebia Therapeutics does not currently have a dividend yield.

Akebia Therapeutics(FRA) AX9

Akebia Therapeutics Financials at a Glance

AX9 News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Akebia Therapeutics

AX9 Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Akebia Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AX9

What is the current price of Akebia Therapeutics?

What is the 52-week range for Akebia Therapeutics?

How much debt does Akebia Therapeutics have?

How much cash does Akebia Therapeutics have on hand?

What is Akebia Therapeutics’s dividend yield?

Premium Investing Services